Sign in

You're signed outSign in or to get full access.

Ken Liddy

Managing Director and Senior Equity Research Analyst at Oppenheimer

Ken Liddy is a Managing Director and Senior Equity Research Analyst at Oppenheimer & Co., focusing on coverage of key companies in the biotechnology and healthcare sectors. He is recognized for detailed analysis of firms such as Amgen, Biogen, and Gilead Sciences, with a strong performance record highlighted by high accuracy scores and top-tier rankings on research platforms like TipRanks. Liddy began his financial services career in the early 2000s, advancing through analytical roles at several major firms before joining Oppenheimer, where he has led sector research since 2015. He holds FINRA Series 7, 63, 86, and 87 licenses, underscoring his expertise and commitment to regulatory standards.

Ken Liddy's questions to Senstar Technologies (SNT) leadership

Question · Q3 2025

Ken Liddy asked about the progress of the MultiSensor technology, identifying the key customers and verticals interested in its deployment, and how customers typically procure these solutions for facilities like prisons. He also questioned the outlook for Q4 and specific regions/verticals, and sought clarification on the nature and amount of the consulting fee.

Answer

CEO Fabien Haubert explained that the first-generation MultiSensor is being broadly tested across various verticals like prisons, utilities, and logistics, often for specific problem spots. The MultiSensor daisy chain has seen initial wins in data centers. He noted that customers often start with one or two units for evaluation before larger deployments. Fabien declined to provide forward-looking statements for Q4 or specific regional/vertical growth but highlighted North America (USA) and Europe as strong areas. He confirmed the consulting fee was a substantial, exceptional, and non-structural part of the G&A increase, without disclosing the exact amount.

Ask follow-up questions

Fintool

Fintool can predict Senstar Technologies logo SNT's earnings beat/miss a week before the call

Question · Q3 2025

Ken Liddy asked about the progress of Senstar's MultiSensor technology, identifying the key verticals and customer types showing interest, and inquired about typical deployment sizes for critical infrastructure like prisons. He also sought insights into the expected performance of the fourth quarter and which regions or verticals are demonstrating the strongest future growth potential.

Answer

Fabien Haubert, Chief Executive Officer, reported that the first-generation MultiSensor is undergoing numerous proofs-of-concept in verticals such as corrections, utilities, and logistics, with increasing interest through distribution. The daisy-chain MultiSensor has secured initial wins in data centers. For deployments, Mr. Haubert noted that customers often start with 1-2 units for evaluation or to address specific issues, with larger orders for new constructions. He refrained from providing forward-looking statements regarding Q4 performance or specific future growth regions/verticals, but highlighted North America (USA) and Europe as strong investment areas and confirmed core verticals are achieving double-digit growth.

Ask follow-up questions

Fintool

Fintool can write a report on Senstar Technologies logo SNT's next earnings in your company's style and formatting